Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

2. juni 2026 opdateret af: Yan Bi, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

A Multicenter Cross-Sectional Study Evaluating the Diagnostic Accuracy of the Liver Inflammation Index for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Patients With Concurrent Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Fatty Liver Disease

This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study is a national, multicenter, real-world, cross-sectional observational trial designed to assess the clinical utility and diagnostic accuracy of the Liver Inflammation Index for identifying Metabolic Dysfunction-Associated Steatohepatitis (MASH) in patients with concurrent Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

The study plans to enroll a total of 10,000 participants across 22 major research centers in China. Data collection will be split into a prospective cohort (9,000 patients) and a retrospective cohort (1,000 patients). Each participating center will enroll between 100 and 2,000 subjects.

Study Procedures and Data Collection:

For all eligible participants, researchers will systematically collect comprehensive clinical data. This includes general demographic information, detailed past medical history, physical examination findings, and lifestyle questionnaires (assessing diet, physical activity, smoking, and alcohol consumption). Clinical assessments will involve standard laboratory tests to calculate the Liver Inflammation Index. Additionally, participants will undergo vibration-controlled transient elastography (using the iLivTouch device) to obtain the Ultrasound Attenuation Parameter (UAP) for steatosis grading and Liver Stiffness Measurement (LSM) for fibrosis staging.

Study Objectives:

The primary objective is to investigate the distribution and alterations of the Liver Inflammation Index in the Chinese T2DM and MAFLD population, and to evaluate the overall detection rate of MASH within this cohort.

Secondary objectives focus on stratifying the MASH detection rate based on several clinical variables:

The presence of comorbidities (including cardiovascular disease, chronic kidney disease, obesity, dyslipidemia, and hypertension).

The degree of hepatic steatosis (S1, S2, and S3), as determined by UAP results.

The severity of liver fibrosis (F0-F1, F2, F3, and F4), as determined by LSM results.

Demographic stratifications, including age, gender, and geographic region within China.

Identification of predictive risk factors associated with MASH in this specific patient population.

Exploratory Endpoints:

The study will explore the impact of modifiable, adverse lifestyle factors on the prevalence of MASH. Furthermore, a 5-year retrospective data collection (where hospital records permit) will be conducted to analyze the relationship between the MASH detection rate and various Liver-Related Events (LREs). LREs are defined as the occurrence of any of the following: Model for End-Stage Liver Disease (MELD) score ≥ 15, liver-related mortality, liver transplantation, progression to hepatocellular carcinoma, esophagogastric variceal bleeding, or hepatic decompensation (including ascites, overt hepatic encephalopathy, bacterial infections, and non-obstructive jaundice).

Undersøgelsestype

Observationel

Tilmelding (Anslået)

10000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Yan Bi, MD,PhD
  • Telefonnummer: 86-25-83-105302
  • E-mail: biyan@nju.edu

Undersøgelse Kontakt Backup

Studiesteder

  • Kina
    • Anhui
      • Bengbu, Anhui, Kina, 233004
        • Rekruttering
        • Department of Endocrinology, the First Affiliated Hospital of Bengbu Medical University
        • Kontakt:
          • Xiaolei Hu
      • Hefei, Anhui, Kina, 230601
        • Rekruttering
        • Department of Endocrinology, the Second Affiliated Hospital of Anhui Medical University
        • Kontakt:
          • Tianrong Pan
      • Wuhu, Anhui, Kina, 241000
        • Rekruttering
        • Department of Endocrinology, the Second Affiliated Hospital of Wannan Medical University
        • Kontakt:
          • Junfei Gu
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510280
        • Rekruttering
        • Department of Endocrinology, Zhujiang Hospital, Southern Medical University
        • Kontakt:
          • Jia Sun
      • Guangzhou, Guangdong, Kina, 511495
        • Rekruttering
        • Department of Obesity and Metabolic Diseases, Panyu Hospital of Traditional Chinese Medicine
        • Kontakt:
          • Hui Li
      • Shenzhen, Guangdong, Kina, 518033
        • Rekruttering
        • Department of Endocrinology, the Eighth Affiliated Hospital, Sun Yat-sen University
        • Kontakt:
          • Yunfeng Shen
    • Guangxi
      • Nanning, Guangxi, Kina, 530021
        • Rekruttering
        • Department of Endocrinology, the First Affiliated Hospital of Guangxi Medical University
        • Kontakt:
          • Yingfen Qin
    • Guizhou
      • Zunyi, Guizhou, Kina, 563000
        • Rekruttering
        • Department of Endocrinology, the Affiliated Hospital of Zunyi Medical University
        • Kontakt:
          • Xin Liao
    • Hainan
      • Haikou, Hainan, Kina, 570311
        • Rekruttering
        • Department of Endocrinology, Hainan General Hospital
        • Kontakt:
          • Kaining Chen
    • Hennan
      • Zhengzhou, Hennan, Kina, 450099
        • Rekruttering
        • Department of Endocrinology, the First Affiliated Hospital of Henan University of CM
        • Kontakt:
          • Suqin Shi
    • Hubei
      • Wuhan, Hubei, Kina, 430060
        • Rekruttering
        • Department of Endocrinology, Renmin Hospital of Wuhan University
        • Kontakt:
          • Ling Gao
    • Hunan
      • Hengyang, Hunan, Kina, 421001
        • Rekruttering
        • Department of Endocrinology, the First Affiliated Hospital of University of South China
        • Kontakt:
          • Xinhua Xiao
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210008
        • Rekruttering
        • Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
        • Kontakt:
        • Ledende efterforsker:
          • Yan Bi, MD, PhD
        • Kontakt:
        • Underforsker:
          • Jin Li, MD, PhD
      • Suzhou, Jiangsu, Kina, 215006
        • Rekruttering
        • Department of Endocrinology, the First Affiliated Hospital of Soochow University
        • Kontakt:
      • Xuzhou, Jiangsu, Kina, 221009
        • Rekruttering
        • Department of Endocrinology, Xuzhou Central Hospital
        • Kontakt:
          • Houfa Geng
    • Shandong
      • Qingdao, Shandong, Kina, 266000
        • Rekruttering
        • Department of Endocrinology, the Affiliated Hospital of Qingdao University
        • Kontakt:
          • Yangang Wang
      • Weifang, Shandong, Kina, 261000
        • Rekruttering
        • Department of Metabolic Diseases and Weight Management, Weifang People's Hospital
        • Kontakt:
          • Haixia Liu
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200000
        • Rekruttering
        • Department of Endocrinology, ZhongShan Hospital, Fudan University
        • Kontakt:
    • Shanxi
      • Xi’an, Shanxi, Kina, 710032
        • Rekruttering
        • Department of Endocrinology and Metabolism, Xijing Hospital, Air Force Medical University
        • Kontakt:
          • Xiangyang Liu
    • Yunnan
      • Kunming, Yunnan, Kina, 650011
        • Rekruttering
        • Department of Endocrinology, the Third People's Hospital of Yunnan Province
        • Kontakt:
          • Li Gui
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310020
        • Rekruttering
        • Department of Endocrinology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
        • Kontakt:
          • Jiaqiang Zhou
      • Wenzhou, Zhejiang, Kina, 325000
        • Rekruttering
        • Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University
        • Kontakt:
          • Hong Zhu

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

The study population consists of adult patients concurrently diagnosed with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Participants will be continuously enrolled from both outpatient clinics and inpatient departments across 22 major research centers and tertiary hospitals located in various geographic regions of China. This cohort represents a real-world clinical population seeking routine medical care, health evaluations, or regular follow-ups for their metabolic and endocrine conditions. Data will be collected through both prospective clinical assessments and retrospective medical record reviews.

Beskrivelse

Inclusion Criteria:

  1. Adults aged ≥18 years, with no restrictions on sex;
  2. Patients clinically diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) according to the Chinese Society of Hepatology guideline Guidelines for the Prevention and Treatment of Metabolic Dysfunction-Associated (Nonalcoholic) Fatty Liver Disease (2024 Edition), and additionally diagnosed with type 2 diabetes mellitus (T2DM) based on the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus (2024 Edition).

Exclusion Criteria:

  1. Presence of unhealed wounds, scars, or other conditions in the right upper abdominal region that are unsuitable for ultrasonographic examination;
  2. Development of other liver diseases during follow-up, including viral hepatitis, drug-induced liver injury, autoimmune liver disease, alcoholic liver disease, or other chronic liver diseases;
  3. History of hepatic decompensation;
  4. History of hepatectomy or liver transplantation;
  5. History of other malignancies;
  6. Presence of vascular liver disease, cystic fibrosis-associated liver disease, sarcoidosis, polycystic liver disease, congenital or rare hereditary liver diseases, mechanical cholestasis, secondary sclerosing cholangitis, or heart failure accompanied by hepatic venous congestion;
  7. History of transjugular intrahepatic portosystemic shunt (TIPS);
  8. Occurrence of acute hepatitis during follow-up (defined as alanine aminotransferase levels >5 times the upper limit of normal) or acute-on-chronic liver failure (ACLF);
  9. Clinical or subclinical hypothyroidism or hyperthyroidism.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
T2DM with MAFLD
Diagnostisk test: iLivTouch (Vibration-controlled transient elastography)
A non-invasive diagnostic assessment performed using the iLivTouch device. This device simultaneously generates three key metrics: the Liver Inflammation Index (the primary target evaluated for its accuracy in detecting MASH), the Ultrasound Attenuation Parameter (UAP) for hepatic steatosis grading, and the Liver Stiffness Measurement (LSM) for fibrosis staging.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
To evaluate the overall detection rate of MASH in the Chinese T2DM and MAFLD population.
Tidsramme: Baseline
Baseline

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Participants with MASH Stratified by Comorbidities
Tidsramme: Baseline
To evaluate and compare the detection rate of Metabolic Dysfunction-Associated Steatohepatitis (MASH) among subgroups of patients with specific concurrent conditions, including cardiovascular disease, chronic kidney disease, obesity, dyslipidemia, and hypertension.
Baseline
Proportion of Participants with MASH Stratified by Hepatic Steatosis Grades
Tidsramme: Baseline
To analyze the differences in the detection rate of MASH across varying degrees of hepatic steatosis (mild [S1], moderate [S2], and severe [S3]), as determined by the Ultrasound Attenuation Parameter (UAP) via transient elastography.
Baseline
Proportion of Participants with MASH Stratified by Liver Fibrosis Stages
Tidsramme: Baseline
To assess the differences in the detection rate of MASH among patients with different stages of liver fibrosis (F0-F1, F2, F3, and F4), as classified by Liver Stiffness Measurement (LSM) via transient elastography.
Baseline
Demographic Variations in MASH Detection Rate
Tidsramme: Baseline
To determine the detection rate of MASH stratified by key demographic factors, specifically gender and predefined age groups, to identify potential population-specific distribution patterns.
Baseline
Geographic Variations in MASH Detection Rate Across China
Tidsramme: Baseline
To evaluate the regional differences in the detection rate of MASH among the enrolled cohort of T2DM and MAFLD patients across different geographical regions within China.
Baseline
Identification of Risk Factors Associated with MASH
Tidsramme: Baseline
To identify and evaluate independent demographic, clinical, and laboratory predictors (risk factors) associated with the presence of MASH using multivariable logistic regression modeling.
Baseline

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Association Between Smoking and Alcohol Consumption Status and MASH Prevalence
Tidsramme: Baseline
Smoking status and alcohol consumption status will be collected at baseline and recorded as binary variables (Yes/No). The association between smoking status, alcohol consumption status, and the prevalence of MASH will be evaluated.
Baseline
Correlation Between MASH Detection and Retrospective Liver-Related Events (LREs)
Tidsramme: Baseline
To analyze the relationship between the current presence of MASH and a history of Liver-Related Events (LREs) by collecting retrospective patient data (where hospital records permit). LREs are defined as the occurrence of any of the following: Model for End-Stage Liver Disease (MELD) score ≥ 15, liver-related mortality, liver transplantation, progression to hepatocellular carcinoma, esophagogastric variceal bleeding, or hepatic decompensation (such as ascites, overt hepatic encephalopathy, or bacterial infections).
Baseline

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Samarbejdspartnere

Fudan University
The Affiliated Hospital of Qingdao University
The First Affiliated Hospital of Soochow University
Xuzhou Central Hospital
Renmin Hospital of Wuhan University
The First Affiliated Hospital of University of South China
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Sir Run Run Shaw Hospital
Hainan General Hospital
First Affiliated Hospital of Wenzhou Medical University
Southern Medical University, China
The Second Hospital of Anhui Medical University
Zunyi Medical College
First Affiliated Hospital of Guangxi Medical University
Weifang People's Hospital
Eighth Affiliated Hospital, Sun Yat-sen University
Panyu Hospital of Traditional Chinese Medicine
The First Affiliated Hospital of Air Force Medicial University
The Third People's Hospital of Yunnan Province
The First Affiliated Hospital of Bengbu Medical University
Second Affiliated Hospital of Wannan Medical College

Efterforskere

  • Ledende efterforsker: Yan Bi, MD,PhD, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

15. maj 2026

Primær færdiggørelse (Anslået)

31. december 2027

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

23. maj 2026

Først indsendt, der opfyldte QC-kriterier

2. juni 2026

Først opslået (Faktiske)

8. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 2026-0142-01

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified participant data may be timely shared with qualified researchers upon request, subject to review and approval.

IPD-delingstidsramme

Data will become available after study completion and primary publication for 3 years.

IPD-delingsadgangskriterier

Data requests require a valid research proposal and signed data use agreement. Approval is contingent on compliance with applicable laws and ethical guidelines.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • ICF

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Type 2 diabetes mellitus (T2DM)

Kliniske forsøg med iLivTouch (Vibration-controlled transient elastography)

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Saudi Arabia

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner